The Remember Me feature is an automatic login process which creates a cookie on the hard drive of your computer containing a unique identifier which ASCO.org will utilize to remember you by, thereby avoiding the need to enter username and password upon subsequent visits to ASCO.org. DO NOT select this option if you share this computer with others since transactional, personal, or member only information will be accessible by other users.

To activate the Remember Me option, click the empty check box when signing in to the site. The Remember Me functionality is deactivated at the logout.

For additional information please review our Privacy Policy.

Concurrent chemoradiation therapy for advanced head and neck squamous cell carcinoma (HNSCC) in a community hospital.

Print

Sub-category:
Head and Neck Cancer

Category:
Head & Neck Cancer

Meeting:
2004 ASCO Annual Meeting

Session Type and Session Title:
General Poster Session, Head and Neck Cancer

Abstract No:
5558

Citation:
Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 22, No 14S (July 15 Supplement), 2004: 5558

Author(s):
M. A. Levine, J. R. Saunders, E. Zinreich, D. Kunar, J. Price, R. M. Hirata, M. Williams; Greater Baltimore Medical Center, Baltimore, MD

Abstract:

Background: Concurrent chemotherapy and radiation therapy have made organ preservation feasible in patients with advanced head and neck squamous cell carcinoma. This study evaluates the use of chemotherapy with hyperfractionated radiation therapy in a community hospital and the importance of elective lymph node dissection for N2 and N3 patients. Methods: Forty-six patients with HNSCC stage III and IV (42/46 male, 35/46 oropharynx, 4 hypopharynx, 7 larynx, 25 N0-1, 21 N2-3) were treated. Median follow-up is 18.7 months (1-46 months). Hyperfractionated radiation therapy was administered twice daily with an interval of at least six hours and a total dose of 7000cGy to the primary site and 5-6000cGy to the adjacent lymph node bearing areas. Chemotherapy was administered during weeks 1 and 6 of radiation therapy and consisted of cis-platin 12mg/M2 IVPB days 1-5 and 5-fluorouracil 600mg/M2 continuous IV infusion over 20 hours days 1-5. Twenty of twenty-one patients with N2-3 disease underwent neck dissection 6-8 weeks following completion of XRT. All pts had insertion of indwelling venous access devices and percutaneous endoscopic gastrostomy tubes. Results: Complete response (CR) at the primary site following chemo-XRT occurred in 45/46 (98%). All pts with N1 achieved CR. 20 of 21 N2-3 underwent neck dissection. Fourteen were downstaged to N0 and six to N1. Two pts died in remission from intercurrent illnesses more than 11 months after completion of therapy. Of the remaining 44 pts, 38 remain NED (86%) (3 pts died from recurrent disease, 2 pts recurred locally and were salvaged surgically, one is alive with metastatic disease). Toxicity: short term, all pts developed confluent mucositis but hospitalization for dehydration or infection was rare; long term, mouth dryness was common but manageable and most pts were PEG independent within three months of completion of therapy. Conclusions:Aggressive chemo-XRT is feasible in a community hospital and affords advanced HNSCC pts the opportunity for organ preservation. Pts with N2 or N3 disease should undergo neck dissection following chemo-XRT since thirty percent of these pts will have node metastases.


  Associated Presentation(s):

    

1. Concurrent chemoradiation therapy for advanced head and neck squamous cell carcinoma (HNSCC) in a community hospital.

Meeting: 2004 ASCO Annual Meeting
Presenter: Marshall A. Levine, MD
Session: Head and Neck Cancer (General Poster Session)


  Other Abstracts in this Sub-Category:

    

1. Phase III randomized trial of radiotherapy versus concurrent chemo-radiotherapy followed by adjuvant chemotherapy in patients with AJCC/UICC (1997) stage 3 and 4 nasopharyngeal cancer of the endemic variety.

Meeting: 2004 ASCO Annual Meeting   Abstract No: 5500   First Author: J. Wee
Category: Head & Neck Cancer - Head and Neck Cancer

    

2. Changing patterns of practice in the management of nasopharynx carcinoma (NPC): Analysis of the National Cancer Database (NCDB).

Meeting: 2004 ASCO Annual Meeting   Abstract No: 5501   First Author: H. Hoffman
Category: Head & Neck Cancer - Head and Neck Cancer

    

3. Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): Results of a phase II study.

Meeting: 2004 ASCO Annual Meeting   Abstract No: 5502   First Author: J. Trigo
Category: Head & Neck Cancer - Head and Neck Cancer

    

More...


  Abstracts by M. A. Levine:

    

1. Randomized phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small cell lung cancer (NSCLC).

Meeting: 2007 ASCO Annual Meeting   Abstract No: 7586   First Author: M. N. Saleh
Category: Lung Cancer - Non-Small Cell Lung Cancer

    

2. Phase II trial of trastuzumab (T), paclitaxel (P) and cisplatin (C) in metastatic (M) or recurrent (R) head and neck squamous cell carcinoma (HNSCC): Response by tumor EGFR and HER2/neu status.

Meeting: 2006 ASCO Annual Meeting   Abstract No: 5511   First Author: M. L. Gillison
Category: Head and Neck Cancer

    

3. Concurrent chemoradiation therapy for advanced head and neck squamous cell carcinoma (HNSCC) in a community hospital.

Meeting: 2004 ASCO Annual Meeting   Abstract No: 5558   First Author: M. A. Levine
Category: Head & Neck Cancer - Head and Neck Cancer

    

More...


  Presentations by M. A. Levine:

    

1. Concurrent chemoradiation therapy for advanced head and neck squamous cell carcinoma (HNSCC) in a community hospital.

Meeting: 2004 ASCO Annual Meeting
Presenter: Marshall A. Levine, MD
Session: Head and Neck Cancer (General Poster Session)

    

More...


  Educational Book Manuscripts by M. A. Levine:

    

No items found.




 
2318 Mill Road, Suite 800, Alexandria, VA 22314   |   phone: (571) 483-1300
© 2005-2009 American Society of Clinical Oncology (ASCO).  All rights reserved worldwide.